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Abstract
Background
Alzheimer’s disease (AD) is a neurodegenerative disorder, which is likely to start as mild
cognitive impairment (MCI) several years before the its full-blown clinical manifestation.
Optical coherence tomography (OCT) has been used to detect a loss in peripapillary
retina nerve fiber layer (RNFL) and a reduction in macular thickness and volume of people
affected by MCI or AD. Here, we performed an aggregate meta-analysis combining results
from different studies.
Methods and Findings
Data sources were case-control studies published between January 2001 and August 2014
(identified through PubMed and Google Scholar databases) that examined the RNFL thick-
ness by means of OCT in AD and MCI patients compared with cognitively healthy controls.
Results
11 studies were identified, including 380 patients with AD, 68 with MCI and 293 healthy con-
trols (HC). The studies suggest that the mean RNFL thickness is reduced in MCI (weighted
mean differences in μm,WMD = -13.39, 95% CI: -17.34 to -9.45, p = 0.031) and, even more
so, in AD (WMD = -15.95, 95% CI: -21.65 to -10.21, p<0.0001) patients compared to HC.
RNFL in the 4 quadrants were all significantly thinner in AD superior (superior WMD = -24.0,
95% CI: -34.9 to -13.1, p<0.0001; inferior WMD = -20.8, 95% CI: -32.0 to -9.7, p<0.0001;
nasal WMD = -14.7, 95% CI: -23.9 to -5.5, p<0.0001; and temporal WMD = -10.7, 95% CI:
-19.9 to -1.4, p<0.0001); the same significant reduction in quadrant RNFL was observed in
MCI patients compared with HC (Inferior WMD = -20.22, 95% CI: -30.41 to -10.03, p =
0.0001; nasal WMD = -7.4, 95% CI: -10.08 to -4.7, p = 0.0000; and temporal WMD = -6.88,
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95% CI: -12.62 to -1.13, p = 0.01), with the exception of superior quadrant (WMD = -19.45,
95% CI: -40.23 to 1.32, p = 0.06).
Conclusion
Results from the meta-analysis support the important role of OCT for RNFL analysis in moni-
toring the progression of AD and in assessing the effectiveness of purported AD treatments.
Introduction
Amongst the various possible causes of dementia, Alzheimer’s disease (AD) is the most com-
mon with an incidence that exponentially increases with age. AD is a brain degenerative disor-
der, where complex relationships between inherited susceptibility and environmental factors
may play roles [1,2]. Because of the slowness of the disease’s progression, the neurodegenera-
tive processes are likely to start many years before the full-blown clinical manifestation of AD.
This variable transitional phase is clinically recognized as a separate entity, mild cognitive
impairment (MCI) [3]. Cognitive and functional severity within the MCI definition varies over
a wide range, so that the syndrome of MCI is not clinically homogeneous [4]. Although sub-
jects with MCI have an increased risk of progressing to dementia, most remain stable or return
to normality [5].
Despite great advances in the understanding of AD pathophysiology in the last few years, the
exact pathogenesis of AD and of its precursor MCI are still not comprehensively understood.
Various visual disturbances may affect AD patients [6–13], which have been historically
attributed to damage and/or degenerative processes in primary and associative visual cortical
areas [14–18]. However, during the last few decades, some authors realized that cortical dys-
functions alone cannot explain entirely the pattern of observed defects [19]. Specifically, multi-
ple forms of evidence points toward the involvement of retinal ganglion cells and their axons in
the optic nerve as a basis of the visual dysfunction in AD [20,21]. In fact, histopathological
lesions associated with AD—neuronal loss, beta-amyloid plaques, neurofibrillary tangles, and
granulovacuolar degeneration—have been seen not only in brain structures historically
thought to be involved in AD [15,16], but also within the neuroretina [20,22].
In the last two decades, several studies have searched for in vivo evidence of the retinal
involvement in AD pathophysiology. Sophisticated imaging techniques have been used, includ-
ing Optical Coherence Tomography (OCT) which has been extensively used to assess the mor-
phological changes of the retina in AD and other dementing disorders. OCT permits the
objective quantification in vivo of the retinal nerve fiber layer (RNFL) that consists of axons
that form the optic nerve axons and contributes partially to the retinal thickness. This method
consists of a non-invasive technology that allows for imaging of the eye [23,24]. Taking in
mind that the human eye is an embryological protrusion of the brain, and the nerves and
axons of the RNFL is a tract of the brain, it is not surprising that OCT has been widely
employed in assessing RNFL thickness in several neurological disorders [25–30]. The OCT
technique for the measurement of the peripapillary RNFL, the macular thickness and volume,
has been proven useful for the detection of significant reduced retinal thickness in patients
with AD [31–36] and in those affected with MCI [37]. Because early diagnosis of AD remains a
big challenge, since up to now can be definitively confirmed only with post mortem histopa-
thology, the discovery of new non-invasive in vivo biological markers is a major aim in current
research on AD [38]. In this context, reduced retinal thickness measured with OCT may be a
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promising biomarker for monitoring progression from normal and abnormal age-related pro-
cesses, such as for instance supranuclear cataract and opacities of ocular lens, to the pathologi-
cal neural degeneration undoubtedly associated with MCI and AD [39]. However, an aggregate
analysis combining results from different studies is lacking. It is thus of particular interest to
assess whether the retinal morphological changes may be related to cognitive impairment.
Only a few published works have attempted correlations between the loss in RNFL and the
neuropsychological indexes of cognitive impairment reported so the results are inconclusive
[40–44].
The intent of this study is to provide a comprehensive meta-analysis overview of the avail-
able results provided by the OCT technique as used to understand morphological retinal
changes that occur due to the degenerative processes associated with AD and MCI.
Materials and Methods
We followed methodology already published elsewhere [45]. In performing this meta-analysis
we followed the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analy-
ses) statement (S1 Fig) [46]. We initially searched the PubMed database to identify articles
published up to August 2014. The search terms used were “Alzheimer’s disease”, “Dementia”,
“Optical coherence tomography”, and “retinal nerve fiber layer”, alone and in combination.
The literature search was updated using the additional keywords “Alzheimer’s disease”, “elec-
troretinogram” and “visual evoked potentials” to identify full-text papers written in English
and published in peer-reviewed journals up to August 2014, using the PubMed and Google
Scholar databases. In addition, we manually searched the reference lists of all primary articles
and review articles. The initial search identified 14 articles (S1 Fig).
Inclusion and exclusion criteria
For inclusion in the meta-analysis a study had to meet the following criteria: (1) case-control
or cross-sectional design; (2) OCT data were reported as mean or standard deviation; (3) AD
and MCI patients were diagnosed according to established diagnostic systems (DSM-III,
DSM-IV, ICD 9, ICD 10); (4) studies should provide the data of peripapillary and/or macular
RNFL thickness; and (5) sample size9 in each group. (5) Only published studies were
included, abstracts were ignored.
We used a two-step selection processes to identify eligible studies. In the first step, two
investigators (GC, VP) screened the title and abstracts and by consensus identified all studies
that did not meet any of the prespecified criteria. We excluded these studies. In the second
step, the same investigators evaluated the full text versions of the remaining studies. Studies
were excluded if they did not meet all criteria.
Data extraction
Two investigators (GC, LZ) independently extracted data and entered them in a customised
database. Disagreements were resolved by consensus. The extracted data included authors and
title of study, year of publication, study design, study size, study participants (AD, MCI, con-
trols), mean age of the participants, severity of the disease (as assessed by MMSE or as classified
in mild, moderate or severe AD), and OCT apparatus type. The parapapillary RNFL thickness
parameters evaluated in these studies were average thickness (360° measurement), temporal
quadrant thickness (316–45°), superior quadrant thickness (46–135°), nasal quadrant thickness
(136–225°) and inferior quadrant thickness (226–315°). All data were extracted from the pub-
lished studies and we did not contact the authors for further information.
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Statistical analysis
Original data were obtained from the articles as much as possible. Data that could not be
obtained were calculated when necessary. When standard deviation (SD) was not available, it
was calculated using the sample sizes, standard error or, if not available, by extrapolating data
from the bar chart. Statistical analysis was performed using custom written software in Mat-
Lab environment (www.mathwork.com) and R statistical software (The R Foundation for sta-
tistical Computing v3.1.2). Summary estimates, including 95% confidence intervals (CIs), were
calculated. For continuous outcome, means and standard deviations were used to calculate the
weighted mean difference using a random-effects model (WMD). The chi-square test, tau2 and
the Higgins I2 test were used to assess heterogeneity [47]. The I2 test is a method for quantify-
ing inconsistency across studies and describes the percentage of variability in effect estimates
that is due to heterogeneity. A value greater than 50% was considered as substantial heteroge-
neity. If there was no heterogeneity across studies (P>0.1, I2,50%), we adopt fixed-effects
model for analysis. Otherwise, random-effects model was used. Potential publication bias was
examined using a funnel plot [48]. A P value less than 0.05 was considered statistically signifi-
cant. A strong correlation between sample size and summary estimates suggests publication
bias.
Results
A total of 14 articles were initially identified; 2 articles were excluded due to duplications, and 1
article due to lack of data. We identified 11 articles on OCT in AD, of which 3 also contained
data inMCI, that were suitable for analysis (see Table 1). However, 2 out of 11 articles were
considered twice [36],[49] in the analysis due to the fact that the participants were scanned
twice, with different OCT apparatus type. Overall, from the 11 studies we included a total of
380 patients with AD, 68 with MCI and 293 healthy controls. For the mean RNFL we identified
10 studies suitable for analysis, which included 349 AD patients, 68 MCI patients, and 263
healthy volunteers. For the quadrant RNFL we identified 8 studies suitable for analysis, which
included 301 AD patients, 45 MCI patients, and 225 healthy controls. The articles included are
described in Table 1 and the main results of the meta-analysis are summarised in Figs 1 and 2.
Meta-analysis of OCT data in AD patients
Analysis of mean RNFL thickness in 11 studies between AD patients and healthy controls found
significant heterogeneity (I2 = 95.65%) across the studies, so the data were pooled through the
random effects model. The meta-analysis of these data showed that the mean RNFL thickness in
AD was reduced significantly compared with healthy controls (WMD = -15.95, 95% CI: -21.65
to -10.21, p<0.0001, Fig 1). Moreover meta-analysis of each quadrant data showed that there
was overall good heterogeneity across studies and a significant difference of RNFL thickness
between the two groups in the all 4 quadrants: superior (I2 = 92.80%, WMD = -24.0, 95% CI:
-34.9 to -13.1, p<0.0001), inferior (I2 = 90.62%, WMD = -20.8, 95% CI: -32.0 to -9.7, p<0.0001),
nasal (I2 = 91.89%,WMD = -14.7, 95% CI: -23.9 to -5.5, p<0.0001), and temporal (I2 = 91.26%,
WMD = -10.7, 95% CI: -19.9 to -1.4, p<0.0001) quadrants. In summary, the results of meta-
analysis showed that there was a significant RNFL thickness reduction in all quadrants in AD
patients compared with the control group.
Meta-analysis of OCT data in MCI patients
Analysis of mean RNFL thickness in 3 studies between MCI patients and healthy controls
found less, but still significant, heterogeneity (I2 = 70.99%) across the studies, so the data were
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Fig 1. Forest plots of weightedmean difference (WMD) of AD patients for the mean and each single quadrant RNFL. Horizontal lines are 95%
confidence intervals.
doi:10.1371/journal.pone.0134750.g001
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Fig 2. Forest plots of weightedmean difference (WMD) of MCI patients for the mean and each single quadrant RNFL.Horizontal lines are 95%
confidence intervals.
doi:10.1371/journal.pone.0134750.g002
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pooled through the random effects model. The meta-analysis of these data showed that the
mean RNFL thickness in MCI was reduced significantly compared with healthy controls
(WMD = -13.39, 95% CI: -17.34 to -9.45, p = 0.031, Fig 2). Moreover meta-analysis of each
quadrant data showed that there was, with the exception of the superior quadrant, an overall
poor heterogeneity across studies: superior (I2 = 91.98%), inferior (I2 = 59.98%), nasal (I2 =
-2.61%), and temporal (I2 = 10.25%). However, data showed significant thinner RNFL in the
inferior (WMD = -20.22, 95% CI: -30.41 to -10.03, p = 0.0001), nasal (WMD = -7.4, 95% CI:
-10.08 to -4.7, p = 0.0000), and temporal (WMD = -6.88, 95% CI: -12.62 to -1.13, p = 0.01),
quadrants with the exception of the superior quadrant where RNFL just tent to be thinner
respect to HC (WMD = -19.45, 95% CI: -40.23 to 1.32, p = 0.06). In summary, the results of
meta-analysis showed that there was a significant RNFL thickness reduction in the mean
and in single quadrants RNFL in MCI patients, with the notable exception of the superior
quadrant.
Publication Bias
From the funnel plot analysis it appears that there is no correlation between study size and
effect size or any other evidence of publication bias (Fig 3).
Discussion
In this review, we performed a comprehensive meta-analysis investigating the role of OCT in
detecting reduced RNFL thickness in AD patients. Since a transient phase may precede the
full-blown clinical manifestation of AD, we examined the role of OCT also in sensing RNFL
thickness changes in MCI. We found that the OCT is a well-suited paraclinical methodology to
assess RNFL thickness in both AD and MCI disorders.
Despite many advances in the understanding of its pathophysiology, AD is still difficult to
diagnose, chiefly because: a) diagnosis is mainly based on psychometric assessments by a multi-
disciplinary team (neurologists, psychiatrists, and psychologist), b) because physical and neu-
rological examinations are not specific for this disorder, and c) because, brain physiological
Fig 3. Funnel plots for evaluating the publication bias. Points indicate weighted mean difference (WMD)
from studies included in meta—analysis of the mean [A], superior [B], inferior [C], nasal [D] and temporal [E]
RNFL quadrants.
doi:10.1371/journal.pone.0134750.g003
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senescence processes may mask the subtle pathological neurodegenerative processes leading to
AD. Because of inter- and intra-individual variability, neurophysiological and neuroimaging
tests have not yet been considered as criteria on which to base a diagnosis. In fact, neurophysio-
logical as well as other paraclinical tests are recommended only on suspicion of secondary
causes of dementia as part of the differential diagnosis of AD. A confirmation of the AD diag-
nosis is possible only with post mortem histopathology. Nonetheless, the last few decades have
seen the use of structural and functional techniques as potential biomarkers that might also
identify factors that may predispose individuals to AD.
The OCT technique for measurement of the peripapillary RNFL, the macular thickness and
volume, has been used as useful tool for the detection of significant retinal changes in patients
and these measures roughly correlate with the severity of the disease.
Results from our meta-analysis based on 11 studies, suggested that AD patients are likely to
have a reduced RNFL thickness as assessed by OCT. This reduction in RNFL thickness, as
observed in most studies on AD patients, was significantly greater than that observed in the
age-matched controls and thus cannot be exclusively ascribed to aging (see a synopsis of pub-
lished OCT studies in AD in Table 1). Further meta-analysis showed a uniform significant
decrease in RNFL thickness in each of the four retinal quadrants, suggesting that whatever fac-
tors cause the degenerative process in AD progression, affect the entire retinal layer.
Although little is known about the neurobiological basis of the physiological and structural
changes that occur in the brain of AD patients, some histological and morpho-functional stud-
ies point to the concept that the same neurodegenerative processes, which affect the brain, may
also affect the nerve fiber layer of the retina, as an integrated part of the nervous system.
In animal models, expressing mutant forms of amyloid precursors, and histological studies
on post mortem human AD eyes, researchers have observed various retinal pathological
changes, such as depletion of axons in the optic nerves and extensive retinal ganglion cell loss
[20,21,50,51]. These changes were accompanied by accumulation within the retina and its
microvasculature of toxic aminoacids classically described in the degenerative processes of AD,
such as fibrillar tau and Aβ aggregates and specific signs of neuroinflammation [52–57].
In investigations using the optic nerve analyser, a higher proportion of AD patients than
age-matched healthy subjects showed signs of optic neuropathy and this manifested as optic
disc atrophy, pathologic optic disc cupping, and thinning of the neuroretinal rim and of the
RNFL [58,59].
In agreement with post mortem studies, OCT data studies indicate a significant decline in
peripapillary RNFL and changes in macular thickness and volume that is progressive from
MCI to AD eyes. Parisi and colleagues first used OCT to study a group of AD patients and
compared them with a group of age-matched controls. In AD patients, OCT results showed a
reduced thickness of the retina NFL overall and in each quadrant examined they found
involvement of the neuroretinal tissue in AD [31,32]. The mean RNFL thickness was con-
firmed to be reduced in AD patients by several independent groups [33–36]. Most studies
observed a significant reduction of RNFL thickness in all quadrants [31,32,36,44], but predom-
inantly in the superior [34,35,37,43,60] and inferior quadrants [34,37]. The retinal thinning in
AD patients was confirmed despite the different commercially available OCT devices used
[36,49].
OCT studies in AD patients showed RNFL thickness reduction that was directly propor-
tional to abnormalities in pattern electroretinogram, reflecting neuronal degeneration in the
retinal ganglion cell layer [31,32], not related to changes in cortical visual evoked responses,
and hence probably not a consequence of retrograde degeneration [60]. Both positive [60,61]
and absent [33,35,37,43,62] correlation was observed between the reduced total macular vol-
ume in patients with AD and the severity of the disease as assessed by the mini mental state
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examination questionnaire (MMSE) [60,61]. Unfortunately, it was not possible to make a sub-
group analysis for this due to lack of power and high variability of the data.
OCT is be a useful tool for evaluating the progression of neurodegenerative processes that
lead to AD. Based on 3 studies, our present meta-analysis showed a significant RNFL reduction
in MCI patients as well compared with age-matched healthy controls. Ancillary quadrant
meta-analysis in MCI revealed a significant reduction in RNFL thickness for each quadrant,
especially in the inferior and nasal, with the exception of the superior, where the reduction
only approached the significance level (p = 0.06). This lack of significance can be ascribed to
the lack of statistical power due to small amount of patients enrolled. Further studies in a large
cohort of patients are needed in order to clarify the exact degree of each quadrant involvement
in MCI. Few studies compared MCI versus AD patients and healthy aged people. Kesler et al.
[37] observed that the mean RNFL was significantly thinner in both AD and MCI patients
groups compared to controls, and that the MCI group fell in between the other two groups.
This difference was particularly prominent in the inferior quadrant, whereas AD patients had
significantly thinner retinal NFL values also in the superior quadrant [37].
Finally, present meta-analysis cannot overcome certain limitations of the literature. First,
the total number of patients is smaller than we would expect to generalize our results, although
our cohort was sufficient to disclose strong statistical significance. Second, the variable assort-
ment of OCT instruments (we counted 7 different apparatus) used across studies prevented us
doing examination of whether differences in RNFL thickness were attributable to different
types of OCT. The latter is of particular relevance for the reproducibility of OCT results in low
compliance patients, considering, among all, the intrinsic between apparatus variability in cen-
tring procedure around the optic disc, eye tracking system, and in length of examination time.
Conclusions
Overall, the results of this meta-analysis showed that RNFL thickness decreased in all quad-
rants in AD patients. These findings strongly suggest that degeneration of retinal ganglion cells
should be added to the constellation of neuropathologic changes found in patients with AD on
the one hand, and that RNFL thickness can be used to distinguish AD patients from normal
ageing, on the other. Moreover, the meta-analysis data also revealed that OCT can be useful to
detect early RNFL abnormalities in MCI patients. Whether the subgroup of MCI patients with
thinner RNFL have a higher annual incidence of conversion to AD [63] remains to be deter-
mined in an appropriately designed study. This is of particular interest in view of using OCT as
a paraclinical test with prognostic value.
Future research in this subject area will surely provide a better assessment of the specificity
of these OCT findings in AD, and their potential correlation with disease severity. We will see
RNFL thickness measurements in patients with other dementias as an aid to diagnosis and we
will see whether the RNFL can be used as a surrogate for magnetic resonance imaging (MRI)
measurements of the brain.
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